The stock of Humacyte Inc. (NASDAQ:HUMA) increased by $0.53 on Tuesday to $4.57, up 13.12 percent. The last five days have seen an average of 784,191 shares of common stock traded. 25 times new highs were reached in the current year, with a gain of $2.43. The average number of shares traded over the last 20 days was 465,233, while the average volume over the last 50 days totaled 545,311.
HUMA stock appreciated 48.37% since last month. On 07/27/23, the company’s shares reached a one-month low of $2.76. The stock touched a high of $5.60 on 05/08/23, after rallying from a low of $1.96 in 52 weeks. The price of HUMA stock has risen by 116.58% or $2.43 this year, reaching a new high 25 times. Still, the stock price is down -18.39% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
HUMA stock investors should be aware that Humacyte Inc. (HUMA) stock had its last reported insider trading activity 61 days ago on Jun 15. On Jun 15, Director Dougan Brady W sold 500,000 shares at $3.12 each. This transaction resulted in the insider making $1,558,750. On Jun 15, Niklason Laura E sold 500,000 shares at a price of US$3.12. After the transaction, the insider now owns 9,990,736 shares. 10% Owner Ayabudge LLC had earlier sold 500,000 shares on Jun 15 for $3.12 a share. The transaction was completed for $1,558,750.
Valuation Metrics
Beta for the stock is 0.99. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 379.06, the price-to-book (PB) ratio of 5.78.
Financial Health
For the three months ended June 29, Humacyte Inc.’s quick ratio was 5.70, while its current ratio was 5.70, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 0.42, and the total debt to equity ratio is 0.61. Based on annual data, it had gross profit of $86.14 million and revenue of $1.56 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. HUMA’s return on assets (ROA) during the last 12 months has been -13.50%. There was a -50.70% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -25.30%.
Earnings Surprise
According to Humacyte Inc.’s quarterly financial report for the quarter that ended June 29, it had $16.41 million in total debt versus $2.11 million in cash and short-term investments. It was predicted that Humacyte Inc.’s quarterly earnings would be -$0.22, but it ended up being -$0.22. EBITDA was -$20.08 million for the quarter. Equity owned by shareholders amounts to $103.33 million.
Technical Picture
Here’s a quick look at Humacyte Inc.’s (HUMA) price momentum from a technical perspective. As of 14 August, the RSI 9-day stood at 83.21%, suggesting the stock is Overbought, with a 121.23% historical volatility rate.
The stochastic %K and %D were 87.98% and 81.48% respectively, while the average true range (ATR) was 0.32. Based on the 14-day stochastic reading of 99.51%, the RSI (14) reading is 76.89%. On the 9-day MACD Oscillator, the stock is at 0.54, and the 14-day reading is at 0.66.
Analyst Ratings
In its most recent analyst report, Piper Sandler raised its rating on Humacyte Inc. (NASDAQ: HUMA) to a Neutral. Prior to this, analysts firm rated the stock as an Underweight. Analysts have assigned Humacyte Inc. (HUMA) an Buy rating. HUMA is a stock that is recommended for selling by 0 brokerage firms, while 1 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 5 others recommend it as a buy.
What is HUMA’s price target for the next 12 months?
The current consensus forecast for the stock is between $3.50 and $16.00, with a median target price of $5.50. In analyzing these forecasts, the average price target given by analysts for Humacyte Inc. (HUMA) is $7.25.
